The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis

Lu Li, Hongliang Xie, Ling Wang, Aolin Zhang, Xuan Mou, Yifan Lin, Hongli Ma, Yu Wang, Jian Li, Jingshu Gao, Chi Chiu Wang, Ping Chung Leung, Xiaohui Fan, Xiaoke WuChinese 2022 · DOI

TL;DR

This systematic review and meta-analysis of 22 randomized controlled trials (RCTs) found that combining Chinese herbal medicine (CHM) with Western medicine (WM) significantly improves treatment outcomes for COVID-19 patients, particularly those with mild to moderate symptoms, without increasing adverse events. This suggests CHM-WM could be a valuable therapeutic approach for COVID-19.

What Problem Does This Paper Address?

The COVID-19 pandemic has presented a significant global health challenge, with a rapid increase in cases and deaths. While Western medicine (WM) offers supportive care and some antiviral treatments, these can have limitations, including potential drug interactions and serious adverse events. Furthermore, there's a continuous need for effective and safe therapeutic options, especially for managing different severities of the disease. Chinese herbal medicine (CHM) has a long history of use in treating respiratory illnesses and has shown potential in managing COVID-19 symptoms. However, rigorous evidence on the combined efficacy and safety of CHM and WM for COVID-19, particularly across different patient severities, has been lacking. This paper aims to address this gap by systematically reviewing and meta-analyzing existing RCTs to provide a comprehensive evaluation of combined CHM-WM therapy.

Methods

The authors conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing combined Chinese herbal medicine and Western medicine (CHM-WM) with Western medicine (WM) alone for COVID-19 patients. They searched multiple databases (CNKI, PubMed, Wanfang, ClinicalTrials.gov, Embase, ChiCTR, ICTRP) for studies published between January 2020 and June 2021. Two independent reviewers assessed trial eligibility, extracted data, and evaluated the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Meta-analysis was performed using Review Manager software. Primary outcomes included the total effectiveness rate, while secondary outcomes encompassed symptom improvement, virological outcomes, CT image improvement, blood test results, and adverse event rates. Subgroup analyses were conducted based on disease severity.

Datasets

Not applicable. This paper is a systematic review and meta-analysis of existing published studies, not a primary research study that collects new data.

Key Insights and Ideas

  • Synergistic Potential: The findings strongly suggest that CHM doesn't just offer an alternative but can synergistically enhance the effects of WM in treating COVID-19. This points towards a more integrated approach to infectious disease management.
  • Targeted Symptom Relief: The significant reduction in specific symptoms like fever, cough, and fatigue with CHM-WM points to CHM's ability to address key clinical manifestations of COVID-19 effectively.
  • Broader Efficacy Beyond Symptoms: The improvements observed in virological outcomes, CT imaging, and blood test markers indicate that CHM-WM might influence the disease process more deeply than just symptom management.
  • Safety Profile: The finding that CHM-WM is associated with fewer adverse events than WM alone is particularly compelling, challenging the notion that adding more treatments inherently increases risk.

Key Results

The meta-analysis included 22 high-quality RCTs involving 1789 participants.

  • Total Effectiveness: Combined CHM-WM treatment showed a significantly higher total effectiveness rate compared to WM alone (Odds Ratio = 2.84, 95% CI = 2.13–3.78). This effect was particularly pronounced in mild and moderate COVID-19 patients.
  • Symptom Improvement: CHM-WM significantly improved various symptoms, including fever, cough, weakness, dry throat, and pharyngalgia, and reduced symptom scores.
  • Virological Outcomes: The mean time to viral assay conversion was significantly shorter with CHM-WM.
  • Radiological and Blood Markers: CHM-WM treatment led to better CT image improvements and favorable changes in blood test markers (e.g., WBC, LYM, CRP levels).
  • Safety: The total adverse event rate was significantly lower in the CHM-WM group compared to the WM group. No serious adverse events or mortality differences were reported between the groups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Variability in CHM Formulas: CHM prescriptions can vary based on individual patient presentation and regional diagnostic classifications, making it challenging to generalize findings to specific formulas.
  • Heterogeneity in Meta-Analyses: Some meta-analyses showed statistical heterogeneity, even when using random-effects models, which could affect the strength of evidence.
  • GRADE Assessment: While the overall quality of evidence for key outcomes was rated as high, some symptom improvement and blood test outcomes had low to high evidence ratings.
  • Lack of Long-Term Data: No studies reported on serious adverse events or long-term outcomes, which warrants further investigation.

The authors suggest that future research should focus on multicenter, large-sample RCTs with strict methodologies to further confirm the effectiveness and safety of combined CHM-WM treatment for COVID-19, especially regarding long-term effects.

Summary updated

Abstract

Current evidence supported the therapeutic effects and safety of combined CHM-WM treatment on COVID-19, especially for patients with mild and moderate symptoms. Long-term effects of therapy are worthy in further study.
BibTeX
@inproceedings{li2022efficacy,
  author = {Lu Li and Hongliang Xie and Ling Wang and Aolin Zhang and Xuan Mou and Yifan Lin and Hongli Ma and Yu Wang and Jian Li and Jingshu Gao and Chi Chiu Wang and Ping Chung Leung and Xiaohui Fan and Xiaoke Wu},
  title = {{The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis}},
  booktitle = {Chinese},
  year = {2022},
  doi = {10.1186/s13020-022-00600-z},
}
Figure